Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 17, Issue 9, Pages 1029-1038Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2013.820708
Keywords
Cancer therapy; cholesterol homeostasis; liver X receptors; oxysterols
Categories
Funding
- Association de Recherche sur les Tumeurs Prostatiques
- Ligues Allier et Puy-de-Dome contre le Cancer
- Fondation ARC de recherche contre le Cancer
- Fondation pour la Recherche Medicale (FRM)
- Fondation BNP-Paribas research grants
- Region Auvergne Programme Nouveau Chercheur
- Region Auvergne
- Fond Europeen de DEveloppement Regional (FEDER)
- Fondation ARC
- Ministry of Education, Research and Technology (MNERT)
Ask authors/readers for more resources
Introduction: Oxysterols are implicated in various cellular processes. Among their target proteins, liver X receptors (LXRs) alpha and beta modulate the cell cycle in a large range of cancer cell lines. Besides their role as cholesterol sensors, LXRs are also involved in the proliferation/apoptosis balance regulation in various types of cancers. Areas covered: This review covers oxysterols and derivatives of cholesterol as well as synthetic or natural ligands (agonist/antagonist) of LXRs. Most tumor cell lines are sensitive to LXR activation. Indeed various cancers are concerned such as prostate, breast, glioblastoma, colorectal, and ovary tumors, and leukemia. Expert opinion: Developing the use of LXR ligands in human health, especially in the field of cancer, represents a novel and promising strategy. Despite a wide spectrum of applications, numerous adverse effects of LXR activation need to be solved before genuine clinical trials in humans. Future directions will be based on the engineering of selective LXRs modulators (SLiMs) as already done for nuclear steroid receptors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available